Selected Grants
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis
Clinical TrialPrincipal Investigator · Awarded by Cabaletta Bio, Inc. · 2024 - 2042HZN-825-302 A multi-center, open-label extension trial to evaluate the efficacy, safety and tolerability of HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis.
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2024 - 2027B Cell-Fibroblast Crosstalk Promotes Chronic GVHD of the Lung
ResearchAdvisor · Awarded by National Institutes of Health · 2024 - 2026A randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety, tolerability and pharmscokinetics of HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2022 - 2025ACV01P - Cost Reimbursable
Clinical TrialPrincipal Investigator · Awarded by Emory University · 2022 - 2024ACE Covid 19 Admin. Supplement: Molecular Regulation of B cells and T cells in Human SLE - Cost Reimbursable
Clinical TrialPrincipal Investigator · Awarded by Emory University · 2021 - 2024Collaborative National Quality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis Scleroderma) Patients
ResearchPrincipal Investigator · Awarded by Scleroderma Research Foundation · 2022 - 2024Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double-Blinded Safety Study - Fixed Price Code
Clinical TrialPrincipal Investigator · Awarded by Benaroya Research Institute at Virginia Mason · 2021 - 2024A trial to evaluate the safety of long term treatment with nintedanib in patients with scleroderma related lung fibrosis.
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2018 - 2023Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Multicenter, Randomized, Double-Blinded Safety Study - Fixed Price Code
Clinical TrialPrincipal Investigator · Awarded by Benaroya Research Institute at Virginia Mason · 2018 - 2023Symptom Clusters in Systemic Sclerosis
FellowshipSignificant Contributor · Awarded by National Institutes of Health · 2020 - 2021An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension
Clinical TrialPrincipal Investigator · Awarded by Reata Pharmaceuticals, Inc. · 2017 - 2021Reata CTD with PAH
Clinical TrialPrincipal Investigator · Awarded by Reata Pharmaceuticals, Inc. · 2016 - 2021Affinergy Scleroderma Antibody study
ResearchPrincipal Investigator · Awarded by Affinergy, LLC · 2018 - 2020Validation of an Algorithm to Identify Incident Interstitial Lung Disease in Patients with Rheumatoid Arthritis
ResearchPrincipal Investigator · Awarded by University of Alabama at Birmingham · 2018 - 2020A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with `Systemic Sclerosis associated Interstitial Lung Disease'(SSc-ILD).
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2016 - 2019STAR Scleroderma
Clinical TrialPrincipal Investigator · Awarded by Cytori Therapeutics, Inc. · 2015 - 2018External Relationships
- Boehringer Ingleheim
- Grand Rounds
- Horizon Pharmaceuticals
- Seattle Genetics
- Talaris
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.